Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants.

Warren, Sophie; Barmpouni, Myrto; Kossyvaki, Vasiliki; Gourzoulidis, George; Perdrizet, Johnna

Warren, Sophie; Barmpouni, Myrto; Kossyvaki, Vasiliki; Gourzoulidis, George; Perdrizet, Johnna.

Afiliação

Warren S; Global Health Economic and Outcomes Research, Pfizer Inc., New York, NY 10001, USA.
Barmpouni M; Pfizer Hellas, 154 51 Athens, Greece.
Kossyvaki V; Pfizer Hellas, 154 51 Athens, Greece.
Gourzoulidis G; Health Through Evidence, 174 56 Athens, Greece.
Perdrizet J; Global Health Economics and Outcomes Research, Pfizer Canada, Kirkland, QC H9J 2M5, Canada.

Vaccines (Basel) ; 11(8)2023 Aug 15.

Article em En | MEDLINE | ID: mdl-37631937